Why Early Phase Speed Depends on Oncology Expertise
In early phase oncology development, speed matters, and sponsors feel it immediately. There is pressure from investors, competition for patients, and the urgency to generate data that will shape the program’s future. But the fastest programs don’t move quickly because they rush. They move quickly because early decisions are made with confidence, informed by oncology expertise.
Early Phase Speed Is Not Just Operational, It’s Scientific
The most consequential early phase decisions are oncology specific. In the early stages of clinical development and protocol planning, teams are making choices about patient populations, dose escalation strategy, cohort design and expansion, endpoints, biomarker feasibility, and site readiness. These decisions determine how efficiently a trial can enroll, how confidently data can be interpreted, and how adaptable the program will be as new information emerges.
When choices are made without deep oncology expertise, programs can appear to start quickly, only to slow later as assumptions are challenged, amendments are required, or feasibility gaps emerge.
Why Speed Without Expertise Creates Risk
Sponsors know that early phase oncology trials leave little margin for error. A protocol adjustment, cohort change, or site reset has multiple implications for clinical development, including time costs and impacts on patient experience, data confidence, and the downstream development strategy.
Because of this high-stakes landscape, sponsors often prioritize oncology specialized expertise when choosing early phase partners. Sponsors are looking for teams that understand the nuances of oncology development, not just protocol execution, and anticipate and plan for future priorities as the program evolves.
Expertise alone isn’t enough; boutique oncology models can deliver strong, early scientific support, but aren’t built to sustain momentum or scale globally as programs progress. A common pitfall is that sponsors rarely feel this limitation at the start, when studies involve just a handful of sites in a single country. Instead, it becomes apparent only as success drives the need to grow and expand across regions.
What Experienced Teams Do Differently
Across early phase oncology programs, a consistent pattern emerges. The teams that move quickly and confidently from the outset tend to:
- Make oncology specific decisions with downstream implications in mind
- Clearly define the scope of work and sponsor oversight so roles, ownership, and decision making are clear
- Build plans that reflect real patient and site realities
Speed in early phase oncology development is about making sure the momentum supports the program instead of working against it. We genuinely embody this because we know that every early decision ultimately affects one thing, which is how quickly meaningful therapies can reach patients who need them.
Continue the Conversation
Attending this year’s ASCO Annual Meeting? Meet with our team of experts to continue the conversation on early phase oncology programs and learn how we can meet your needs. Book a meeting today.
